Risperdal Lawsuits Surpass 1,000 in Pennsylvania Litigation, Bernstein Liebhard LLP Reports

Share Article

The Firm is representing numerous Risperdal lawsuit clients who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication.

Free Case Review
Our Firm continues to represent numerous plaintiffs in Risperdal lawsuits that allege male breast growth, or gynecomastia.

Risperdal lawsuit (http://www.risperdallawsuit2014.com/) records surpassed 1,000 this month in a consolidated Pennsylvania litigation established for cases involving the antipsychotic medication, Bernstein Liebhard LLP reports.

As of mid-November, a total of 1,012 Risperdal filings were listed on the website for the Philadelphia Court of Common Pleas, suggesting a continued increase in the number of lawsuits filed against the drug’s manufacturers. Lawsuits now pending in Philadelphia state court similarly accuse the Johnson & Johnson subsidiary, Janssen Pharmaceuticals, of failing to adequately warn patients about its potential to cause gynecomastia, a condition referring to male breast growth, and other side effects. As a result, plaintiffs allege severe physical and psychological trauma caused by the medication. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

“As our Firm continues to represent numerous plaintiffs in Risperdal lawsuits that allege male breast growth, or gynecomastia, we are pleased to see more cases filed in the Philadelphia litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Risperdal. The Firm continues to offer free and confidential case reviews to men and young boys who allegedly developed gynecomastia following their use of Risperdal.

Risperdal Lawsuits

Risperdal lawsuits now pending in Pennsylvania were similarly filed by individuals who were allegedly injured by the atypical antipsychotic medication, which is approved by the U.S. Food and Drug Administration (FDA) to treat adults and adolescents ages 10-to-17 with schizophrenia or bipolar disorder, as well as children whose irritability symptoms are associated with autism. Recent research suggests that Risperdal is also prescribed for patients with ADHD, although it has not been specifically cleared for this use by regulators.*

Many of the Risperdal lawsuits in Philadelphia similarly allege complications of male gynecomastia, which may include breast tenderness, swelling and nipple discharge, according to plaintiffs. Johnson & Johnson and Janssen failed to properly warn about these risks, which are caused by the drug’s tendency to produce elevated levels of prolactin, a hormone associated with female breast development and lactation in new mothers, Risperdal lawsuits further allege.

Johnson & Johnson and Janssen have also been accused of promoting the medication off-label for uses not approved by the FDA in lawsuits filed in Philadelphia state court, as well as by the federal government. In November 2013, the companies agreed to pay the U.S. Department of Justice more than $2.2 billion to resolve claims that involved their alleged off-label marketing of Risperdal to elderly patients with dementia and certain pediatric uses not cleared by the FDA until 2006. According to the federal government, this was one of the largest federal case settlements involving healthcare fraud in history.

Men and boys who allegedly developed gynecomastia due to their use of Risperdal may be able to recover compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about the alleged association between Risperdal and gynecomastia, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website